<DOC>
	<DOCNO>NCT00014222</DOCNO>
	<brief_summary>RATIONALE : 1. . To compare effect breast cancer three different combination drug commonly use treat disease . 2. . It yet know treatment regimen effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy give without epoetin alfa treat woman undergone surgery stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Colony-stimulating Factors Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare disease-free survival premenopausal early postmenopausal woman previously resect node positive high-risk node negative stage I-IIIB breast cancer treat cyclophosphamide , epirubicin , fluorouracil v cyclophosphamide , epirubicin , filgrastim ( G-CSF ) , epoetin alfa follow paclitaxel v cyclophosphamide doxorubicin follow paclitaxel . Secondary - Compare overall survival patient treat regimen . - Compare rate toxic effect regimens patient population . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord number positive node ( 0 vs 1-3 vs 4-10 v 10 ) , type prior surgery ( total v partial mastectomy ) , estrogen receptor status ( positive v negative ) . Patients randomize one three treatment arm . - Arm I : Patients receive epirubicin IV fluorouracil IV day 1 8 oral cyclophosphamide day 1-14 . Treatment repeat every 28 day 6 course . - Arm II : Patients receive epirubicin IV cyclophosphamide IV day 1 filgrastim ( G-CSF ) subcutaneously ( SC ) day 2-13 . Patients hemoglobin &lt; 13.0 g/dL also receive epoetin alfa SC weekly begin within 1 week start therapy continue need . Treatment repeat every 14 day 6 course . Beginning 21 day completion epirubicin cyclophosphamide , patient receive paclitaxel IV 3 hour day 1 G-CSF epoetin alfa . Treatment repeat every 21 day 4 course . - Arm III : Patients receive doxorubicin IV 15 minute cyclophosphamide IV 15 minute day 1 . Treatment repeat every 21 day 4 course . Beginning 21 day completion doxorubicin cyclophosphamide , patient receive paclitaxel arm II . Treatment arm continue absence disease progression unacceptable toxicity . All receptor positive patient receive oral tamoxifen anastrozole ( tamoxifen contraindicate ) 5 year completion chemotherapy . Quality life assess baseline , day 1 cycle 2 , 3 4 6 ( arm I ) , day 1 cycle 3 day 1 cycle 1 4 paclitaxel ( arm II ) , day 1 cycle 2 3 , day 1 cycle 1 4 paclitaxel , ( arm III ) , 9 month , 12 month , annually thereafter 5 year Patients follow 9 month , 12 month , every 4 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 2,100 patient ( 700 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast potentially curable T04 ( dermal involvement pathology assessment ) , N02 , M0 No clinical T4 disease Previously treat one following : Total mastectomy level II axillary node dissection Partial mastectomy level II axillary node dissection plan breast radiotherapy completion adjuvant chemotherapy regimen* Patients positive sentinel node biopsy must undergo level II axillary node dissection sufficient nodal sample If microscopic residual situ invasive disease present total partial mastectomy margin , plan radiotherapy must also include boost tumor bed No residual tumor axilla dissection Axillary node positive Negative node allow tumor ≥ 1 cm 1 follow criterion define highrisk nodenegative disease meet : Histological grade III , Estrogen receptor negative , Lymphatic/vascular invasion Hormone receptor status : Estrogen receptor status know PATIENT CHARACTERISTICS : Age : 60 Sex : Female Menopausal status : Pre postmenopausal Performance status : ECOG 02 Life expectancy : At least 5 year Hematopoietic : WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic : Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Renal : Creatinine ≤ 1.5 time ULN Cardiovascular : LVEF ≥ limit normal MUGA echocardiogram No arrhythmia require ongoing treatment No congestive heart failure No document coronary artery disease Other : No malignancy except : Adequately treat basal cell squamous cell skin cancer carcinoma situ cervix Ductal lobular carcinoma situ curatively treat surgery alone Other prior malignancy ( except breast cancer ) curatively treat 5 year prior study entry No serious underlie medical illness psychiatric addictive disorder would preclude study compliance No known hypersensitivity E. coliderived product , mammaliancell derive product , study agent Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy breast cancer No concurrent pegfilgrastim darbepoetin alfa ( Arm II ) Allowed arm 1 3 medically necessary Chemotherapy : No prior chemotherapy breast cancer Endocrine therapy : No prior hormonal therapy breast cancer No concurrent hormone replacement therapy No concurrent selective estrogenreceptor modulators ( e.g. , raloxifene treatment prevention osteoporosis ) No concurrent oral contraceptive ( i.e. , birth control pill ) No concurrent aromatase inhibitor Radiotherapy : See Disease Characteristics No prior radiotherapy breast cancer Surgery : See Disease Characteristics No 12 week since prior total partial mastectomy ( include reexcision margin ) Other : At least 30 day since prior investigational drug No concurrent investigational drug Concurrent bisphosphonates treatment prevention osteoporosis allow</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>